These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24918664)

  • 1. Regulatory B cells present in lymph nodes draining a murine tumor.
    Maglioco A; Machuca DG; Camerano G; Costa HA; Ruggiero R; Dran GI
    Medicina (B Aires); 2014; 74(3):185-8. PubMed ID: 24918664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1-6 cells.
    Wang LK; Kuang M; Hua YP; He Q; Chen B; Wang Y; Peng BG
    J Surg Res; 2013 Aug; 183(2):900-6. PubMed ID: 23481561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.
    Thomas SN; Vokali E; Lund AW; Hubbell JA; Swartz MA
    Biomaterials; 2014 Jan; 35(2):814-24. PubMed ID: 24144906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased B Regulatory Phenotype in Non-Metastatic Lymph Nodes of Node-Positive Breast Cancer Patients.
    Mehdipour F; Razmkhah M; Hosseini A; Bagheri M; Safaei A; Talei AR; Ghaderi A
    Scand J Immunol; 2016 Mar; 83(3):195-202. PubMed ID: 26708831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
    Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
    Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression.
    Nakamura S; Yaguchi T; Kawamura N; Kobayashi A; Sakurai T; Higuchi H; Takaishi H; Hibi T; Kawakami Y
    J Immunother; 2014; 37(2):63-72. PubMed ID: 24509168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
    Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
    Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.
    Fu EJ; Arca MJ; Hain JM; Krinock R; Rado J; Cameron MJ; Chang AE; Sondak VK
    J Immunother; 1997 Mar; 20(2):111-22. PubMed ID: 9087383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
    Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
    J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory B cells preferentially accumulate in tumor-draining lymph nodes and promote tumor growth.
    Ganti SN; Albershardt TC; Iritani BM; Ruddell A
    Sci Rep; 2015 Jul; 5():12255. PubMed ID: 26193241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of antigen-specific regulatory T cells in the liver-draining celiac lymph node following oral antigen administration.
    Hultkrantz S; Ostman S; Telemo E
    Immunology; 2005 Nov; 116(3):362-72. PubMed ID: 16236126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer.
    Battaglia A; Buzzonetti A; Martinelli E; Fanelli M; Petrillo M; Ferrandina G; Scambia G; Fattorossi A
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1546-53. PubMed ID: 20338481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics.
    Lund AW; Duraes FV; Hirosue S; Raghavan VR; Nembrini C; Thomas SN; Issa A; Hugues S; Swartz MA
    Cell Rep; 2012 Mar; 1(3):191-9. PubMed ID: 22832193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of CD4+ CD25+ regulatory T-cells detection in tumor-draining lymph nodes of nonsmall cell lung cancer patients].
    Su YJ; Ren K; Li H; Ren XB; Wang CL
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):922-6. PubMed ID: 18478932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
    Roberts LK
    J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The balance of regulatory and stimulatory B cell subsets in breast cancer draining lymph nodes correlates with tumor prognostic factors.
    Shariati S; Mehdipour F; Samadi M; Rasolmali R; Talei AR; Ghaderi A
    Life Sci; 2020 Sep; 257():118117. PubMed ID: 32693243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes.
    Faghih Z; Erfani N; Haghshenas MR; Safaei A; Talei AR; Ghaderi A
    Immunol Lett; 2014; 158(1-2):57-65. PubMed ID: 24326038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.